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Acute cyclosporine renal dysfunction reversed by dopamine infusion in
healthy subjects. Up to now, no studies have been performed in normal
humans to investigate the role of renal hemodynamic abnormalities in
relation to acute-cyclosporin A (CsA) renal dysfunction and to verify
whether the specific renal vasodilator, dopamine, can counteract these
abnormalities. Eight normal subjects were examined both (A) after oral
CsA (12 mg/kg body wt) and (B) after oral CsA + dopamine infusion (2
mg/kg body wt/min), under water diuresis. Both in protocols A and in
B, four basal renal clearances were performed before CsA and every
twenty minutes for four hours after CsA administration. In protocol A,
after CsA, inulin (GFR) and PAH clearance (RPF) fell by up to 27% and
to 41%, respectively, so that filtration fraction (FF) increased (P <
0.01). A slight (not significant) hypertension occurred while renal
resistances were markedly raised (P < 0.001). Fractional urine and Na
excretion as well as CH,o decreased, while Uosm increased (P < 0.01).
In protocol B, dopamirie was infused from 120 to 180 minutes after CsA
(that is, when the maximal adverse effects of CsA on renal hemody.
namics had been observed in A). Dopamine infusion could reverse
completely the effects of CsA on RPF, GFR, fractional urine output and
CH2O; only U0,,, remained higher than normal in conjunction with an
increased fractional excretion of sodium (P < 0.01). No changes were
observed in plasma renin activity, aldosterone and in urinary epineph-
rine and norepinephrine excretion both in protocols A and B. In
conclusion, our data indicate that, in normal humans: (I) a single-dose of
CsA (12 mg/kg body wt per oz) causes marked renal vasoconstriction,
impairment in GFR, increase in FF and proximal tubular overreabsorp-
tion with fall of fractional urine and sodium excretion and, conse-
quently, reduction in the renal ability to generate free-water (CH,O); (ii)
the acute changes of glomerular and tubular function observed after oral
CsA are accounted for by primary reversible alterations in renal
hemodynamics; (iii) these effects are completely reversed by dopamine
infusion at low dosage.
Nephrotoxicity is the main limiting factor to a more extensive
use of cyclosporin A (CsA) in the immunological management
of transplants and autoimmune diseases: sixty to ninety percent
of patients treated with CsA develop impairment of renal
function [1]. Its mechanism(s), however, is still unclear in spite
of several studies performed both in experimental animals and
in humans [2—81. Whether the CsA-induced renal dysfunction is
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due to a direct tubulo-interstitial toxic effect [5, 9—11] or to a
renal vasoconstriction [4, 12—141 remains an unanswered ques-
tion.
In experimental animals the acute hemodynamic effects oc-
cur almost instantaneously after i.v. administration of CsA
when renal blood flow is measured by electromagnetic flow
probe [15]. Therefore, the hemodynarnic changes might precede
tubulo-interstial damage. The histopathological lesions, in fact,
are detected after repeated administration of CsA and consist
predominantly of proximal tubular lesions [161. These morpho-
logic changes are, however, nonspecific [161 and can be sec-
ondary to the ischemia due to renal vasoconstriction [17].
Hitherto, no studies on the acute effects of CsA on renal
hemodynamics and tubular function have been carried out in
renal patients or in healthy subjects. Since it is not possible to
exclude some renal dysfunction in patients with organ allograft
or with autoimmune diseases [5, 6, 18], we decided to study the
functional effects of CsA on the kidney of healthy subjects.
In laboratory animals, various attempts have been made to
clarify the pathogenesis of acute CsA nephrotoxicity and to
prevent renal functional impairment [3, 19—221 by vasodilating
agents, The results of these studies were not conclusive; in
particular, vasodilating drugs generally showed a partial revers-
ibility of the reduced GFR. The efficacy of vasodilators in
preventing CsA nephrotoxicity in humans has been poorly
evaluated [23], and never by prospective studies. Dopamine at
low dosage is known to increase renal blood flow and GFR by
acting on specific intrarenal receptors without causing systemic
pressure effects; for this property, it has been used to evaluate
the renal functional reserve in normal subjects [24J. It has also
been used to ameliorate the clinical course of patients with
organic acute renal failure [25].
The present studies were, therefore, designed to investigate
in normal humans the role of renal hemodynamic abnormalities
in relation to acute glomerular and tubular dysfunction induced
by CsA and to test the possibility that the specific renal
vasodilator, dopamine, can counteract these abnormalities. A
single-dose CsA administration either alone or associated with
dopamine infusion in healthy subjects appeared to be the most
suitable model for assessing the functional effects of CsA in a
condition in which histopathological damage could not occur
[26].
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Methods
Subjects
The studies were performed in eight healthy male volunteers,
all physicians of our Unit aged 25 to 36 years (mean: 28).
Informed written consent was obtained from each of them after
explanation of the experimental protocol as well as CsA and
dopamine side-effects. The subjects were taking no medications
for at least one month before the study; the use of alcohol,
tobacco, tea, and coffee was prohibited for at least one day
before the study. Beginning one week before and during the
whole study, all subjects received a controlled diet with con-
stant intake of protein (1 g/kg of body wt), sodium (170 mmol
per day), potassium (40 mmol per day) and calories (30 kCal/kg
of body wt). A period of stabilization was allowed until the
magnitude of changes in creatinine clearance, urinary sodium
and potassium excretion did not exceed 10% in three consecu-
tive days.
Clearance methods
All subjects were studied by renal clearance methods during
maximal water diuresis (induced by 20 ml of water/kg of body
wt per os in 20 mm and maintained by 20 mI/mm of 5% glucose
i.v.). The increase in urine flow induced by water diuresis, in
fact, permits several clearance periods in a relatively short
time. When a steady state of urine flow had been obtained (that
is, when the magnitude of changes in urine volume did not
exceed 10% in three consecutive periods), renal clearances
were performed. The subjects were allowed to stand during
voiding, and to sit in the intervening period. A solution of inulin
and PAR (6 g of inulin and 4 g of PAH in 500 ml of NaCI 0.9%)
was infused i.v. at a rate of I mI/mm to maintain plasma
concentrations of inulin at 15 to 20 mgldl and PAH at 1.5 to 2.0
mg/dl. A 60-minute equilibration period was allowed after the
start of infusion for the achievement of steady plasma levels of
inulin and PAH.
Two different studies (A and B) were performed in the same
eight subjects.
Protocol A: Cyclosporin study
After a steady urine volume was achieved, four accurately-
timed urine collections of twenty minutes were obtained by
spontaneous voiding before giving CsA orally at the dosage of
12 mg/kg of body wt. Three clearance periods per hour were
then performed in the four hours following CsA administration.
This time period of four hours was chosen on the basis of
previous studies of CsA pharmacokinetics [27], in which a
single oral dose of CsA, administered in healthy subjects,
determined a peak of blood CsA concentration from two to four
hours after drug administration. Blood samples were collected
at the beginning and the end of each clearance period for
determination of plasma inulin, PAR, creatinine, urea, sodium,
potassium, chloride, osmolality, aldosterone, renin activity,
blood CsA levels and hematocrit. Urinary samples were ana-
lyzed for determination of inulin, PAH, creatinine, urea, so-
dium, potassium, chloride, osmolality and catecholamines (nor-
epinephrine and epinephrine). Blood pressure and heart rate
were monitored every ten minutes throughout the study. Renal
blood flow (RBF) was calculated from renal plasma flow (RPF,
PAH clearance) and hematocrit. Mean arterial pressure was
calculated as the sum of the diastolic pressure plus 1/3 of the
difference between systolic and diastolic pressure. Renal vas-
cular resistance (RVR) was calculated by dividing the mean
arterial pressure by RBF.
Protocol B: Cyclosporin plus dopamine study
On the basis of data of protocol A, a second study was
performed following the same protocol, but with the addition of
an i.v. infusion of dopamine (2 pg/kg of body wt/min) in 5% of
glucose for 60 mm, from the beginning of the third hour after
CsA administration. After the end of dopamine infusion, three
further clearance periods (4th hour) were performed. Clearance
measurements were identical as in protocol A.
Laboratory procedures
Inulin and PAH concentrations were determined by tech-
niques that have been previously described [281. In all analyti-
cal determinations the standard curves of inulin and PAH were
determined by linear regression analysis; the correlation coef-
ficient of these curves was always greater than r = 0.996.
Sodium and potassium were measured by a flame photometer;
chloride, creatinine and urea by a Technicon AutoAnalyzer;
osmolality by an osmometer (Model 250 D, Fiske Associates
Inc., Uxbridge, Massachusetts, USA). Plasma renin activity
was measured by radioimmunoassay of angiotensin I and aldo-
sterone by standard radioimmunoassay, as previously de-
scribed [291; blood levels of CsA were measured by radioim-
munoassay of polyclonal antibodies (Sandoz LTD, Basle,
Switzerland). Urinary excretion of norepinephrine and epineph-
rifle were determined by fluorometric assay on acidified urine as
described elsewhere [30]; urinary determination was chosen as
a better estimate of adrenergic activity than plasma cathechola-
mines levels, because of the very short half-life of these
hormones [31].
Statistical analysis
All the clearance data have been corrected for a body surface
area of 1.73 m2. Data are presented as means and standard
errors. Analysis of variance for repeated measures and linear
regression analysis were used. P values less than 0.05 were
considered statistically significant.
Results
Since the four clearances for the determination of above-
mentioned parameters before CsA were not different in the
study A and in the study B, the means of these four clearance
periods were used as basal values.
Protocol A: Cyclosporin study
As shown in Figure 1, CsA caused a decrease of both inulin
(C1) and PAH (CPAH) clearances, which became significant at
Tl00 and at T60 minutes after CsA administration, respectively.
C1,, in fact, fell significantly from a basal value of 121.9 (5.4 SE)
mi/mm to 92.3 (7.5 SE; P < 0.01) at TlOO minutes and remained
decreased thereafter; CPAH fell from 581.1 (73.5 SE) to 396.6
(88.7 SE) mI/mm (P < 0.001) at T100 minutes and remained low
thereafter, The FF was significantly increased in any clearance
period from TlOO to 240 minutes after CsA administration:
during the control period, FF was equal to 20.5% (1.6 SE) while
during the period from T100 to T240 it ranged from 23.0% (2.4
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Fig. 2. Effects of cyclospormne administration on
absolute (V: I———l) and fractional (V/C,,,: i—i)
urine output.
as fractional urine output (V/C1, from TlOO to T240). Frac-
tional excretion of sodium was reduced in any clearance period
from Tl00 to T240 after CsA administration, being equal to
1.9% (0.3 SE) during control period and ranging from 1.2% (0.2
SE) at T140 minutes (P < 0.05) to 0.8% (0.2 s) at T200 minutes
(P C 0.01) during CsA administration. A similar reduction was
observed in fractional excretion of chloride. The ratio UcjPcr
and UUjPU, were significantly increased in relation to control
values in any clearance period from TlOO to T240 minutes.
Neither plasma potassium concentration nor fractional excre-
tion of potassium were changed by CsA administration.
As showed in Figure 3, the minimum urinary osmolality
(Uosm) in basal condition (TO) averaged 62.2 mOsm/kg of H20
(2.9 se); it increased significantly after CsA, already at T80
minutes, up to a maximum value of 98.1 mOsmlkg of H70 (13.5
I I I I I I I I I
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SE; P C 0.05) to 27.9% (1.4 SE; P < 0.001). Since mean arterial
pressure increased only slightly by 2 to 3 mmg after CsA
administration (but not significantly), mean renal vascular re-
sistances were markedly raised from the T60 to T240 minute
clearance periods (P C 0.01). Mean values of heart rate re-
mained unchanged throughout the study (range 74 to 77 beats
per mi. Creatinine clearance was significantly reduced by
CsAadministrationonlyatTl8O(14O.9 + 7.1 srvs. 117.2 + 9.5
sE; P C 0,05) and did not show a fall below 90 mI/mm in any
subject. Paired measurements of creatinine and inulin clearance
performed before and during CsA showed a highly significant
relationship between the two indexes of GFR (r = 0.975, P C
0.001).
As shown in Figure 2, urine output (V) was significantly
reduced by CsA both as absolute value (from T60 to T240) and
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SE) at T140 minutes, and remaining stable thereafter. The
fractional free-water generation was significantly reduced by
CsA from a mean value of 13.1 mI/mm (0.9 SE) at TO to a
minimum mean value of 7.9 mI/mm at 140 minutes (1.4 SE),and
remaining significantly lower than the basal value thereafter.
Blood CsA concentrations averaged about 1000 ng/ml at the
second hour after CsA and about 1500 ng/ml at the third and the
fourth hour after CsA. No relationship between blood levels of
CsA and any of the considered parameters was detected.
Plasma renin activity averaged 2.5 ng/ml/hr (0.6 SE) during the
control period and remained unchanged after CsA administra-
tion (range 2.4 to 2.5 ng/ml/hr); the plasma aldosterone level
was 55.9 pg/mI (4.7 SE) at TO and did not change during CsA
administration (range 60.6 to 80.6 pg/mI). Urinary excretion of
epinephrine and norepinephrine at TO averaged 2.3 (0.3 SE) and
6.0 (0.4 SE) pg/hr, respectively, and remained unchanged after
CsA administration (1.6 to 2.2 and 4.7 to 6.0 pg/hr, respective-
ly).
Protocol B: Cyclosporin plus dopamine study
As shown in Figure 4, when the infusion of dopamine was
started at the beginning of the third hour (at the maximum
impairment of renal function in protocol A after CsA adminis-
tration), a prompt and complete return of C1 and CPAH (and
FF) to control values was observed and lasted until the end of
dopamine infusion. The withdrawal of dopamine infusion was
then followed by an immediate fall of both C1, and CPAH. Paired
measurements of inulin and creatinine clearance performed
before and after CsA administration showed a highly significant
relation between the two indexes of GFR (r = 0.979,P < 0.001).
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Fig. 4. Effects of cyclosporine plus dopamine
administration on inulin (C,,,: i— — —i) and PAH
clearance (CPAH: —F).
rr
0 60
Dopamine infusion
I I I I I I
80 100 120 140 160 180
Time, minutes
—f_-I I
200 220 240
1090
23 -
21 -
19
17 -
-
15-
E
> 13 -
11 —
9-
7-
Conte et a!: CsA and dopamine in healthy patients
Urine output, which was depressed by CsA before dopamine
infusion, returned to the control value during dopamine infusion
both as absolute and fractional values, to fall again after
dopamine withdrawal (Fig. 5). Under the effect of CsA alone
(during the 2nd and the 4th hour of protocol B) a significant fall
in fractional excretion of sodium (FENa) and in fractional
free-water clearance (Fig. 6) was observed in a fashion similar
to that of protocol A. The i.v. infusion of dopamine during the
third hour of protocol B had a natriuretic effect: FENa ranged
from 2.3% (0.2 SE) to 2,7% (0.2 SE) above the control values of
1.8% (0.1 SE). As shown in Figure 6, the increase of minimum
Uosm after CsA administration, already observed in protocol A,
was even greater during and after dopamine infusion. Never-
theless, fractional free-water clearance was normalized (that is,
increased) by dopamine infusion (Fig. 6). PRA averaged 1.5
ng/ml/hr (0.3 SE) during the control period and was unchanged
during dopamine infusion (range 1.5 to 1.8 nglmllhr). The
plasma aldosterone level averaged 86.9 pg/ml (15.1 SE) in
control conditions and was unchanged during dopamine infu-
sion (range 80.6 to 100.0 pg!ml). Urinary excretion of epineph-
rine and norepinephrine at TO averaged 2.5 (0.2 SE) and 6.2 (0.3
SE) gIhr, respectively, and was unchanged during dopamine
infusion (2.4 to 2.5 and 6.0 to 6.2 gIhr, respectively). Blood
concentrations of CsA did not differ from values of protocol A,
averaging about 1000 ng/ml at the second hour after CsA and
about 1350 nglml at the third and the fourth hour after CsA. No
relationship between blood levels of CsA and any of the
considered parameters was detected. Finally, dopamine infu-
sion did not modify mean values of arterial pressure and heart
rate.
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Discussion
After a single oral administration of CsA in healthy subjects
(12 mg/kg of body wt), in a dose similar to that proposed in the
early phase of organ allograft [16], we have observed a rapid,
progressive impairment of renal function: C1, and CPAH, in fact,
were already reduced after about one hour, reaching steadly the
lowest values from the second hour on. The striking fall of
CPAH was associated with a moderate decrease of C1,,, so that
FF increased significantly. These changes of renal function are
usually observed in laboratory animals and in humans during
prerenal acute failure [171. The nonproportional decrease of
CPAH and C1,, after CsA administration was likely due to a
disequilibrium of glomerular pressures at the efferent end of the
glomerular capillary network, as demonstrated in dogs and
hypothesized in men [32], so that GFR is not plasma flow
dependent. The resulting increase of filtration fraction, by
raising the oncotic pressure in peritubular capillaries, is ex-
pected to cause proximal overreabsorption of tubular fluid [33].
This proximal overreabsorpticn did presumably occur in our
normal subjects after CsA administration, as suggested by the
decrease of urine output and free-water clearance. Other stud-
ies, performed after short-term CsA administration both in
experimental animals and in humans, have demonstrated an
increased proximal fractional reabsorption [14, 18, 34]. The
evaluation of the diagnostic indexes commonly used for differ-
entiating "prerenal" acute failure from acute tubular necrosis
(FENa, Uosm, U/Pcr, U/Pur, etc.) indicates that the CsA
induced impairment of renal function "mimics" the condition
of functional renal insufficiency caused by renal hypoperfusion,
suggesting an arteriolar vasoconstriction as the primary renal
effect of CsA when given acutely. These observations have
relevant clinical implications: our findings, observed during
acute CsA nephrotoxicity, are similar to those shown by other
authors during the early stage of renal rejection [35].
Undoubtedly, measurement of renal plasma flow by CPAH
without determination of PAH extraction has an important
drawback in that CPAH does not represent effective renal
plasma flow, neither in healthy subjects nor when renal function
is impaired by CsA [4]. After acute administration of CsA in
rats, however, Dieperink et al [19] did not find any significant
difference between CPAH and effective renal plasma flow mea-
sured by PAH extraction. In our acute study, CsA caused only
a moderate impairment of Ci,,. In agreement with other authors
[13], it is reasonable to argue that in such a condition CPAH can
be considered a reliable index of renal plasma flow.
It is well known that dopamine interacts in the kidney with
specific dopaminergic receptors and reduces glomerular arteri-
olar resistances, thereby improving renal cortical perfusion
[24]. In our CsA + dopamine study, in spite of blood levels of
CsA similar to those obtained during CsA study, the infusion of
dopamine at dopaminergic dosage was able to completely
reverse the marked renal vasoconstriction, the impairment in
GFR and the depressed fractional urine output. These modifi-
cations occurred with no changes in blood pressure nor in heart
rate. According to the worldwide literature, attempts to protect
laboratory animals from CsA by other agents, such as phenox-
ibenzamine [20], tromboxane inhibitors [9], nifedipine [20],
captopril [3, 20, 22], and prostaglandin [20, 36], have not led to
complete correction of GFR impairment induced by CsA.
The reversibility of the renal effects of CsA by dopamine
infusion, the reappearance of renal CsA impairment immedi-
ately after dopamine withdrawal and the rapidity by which the
reversion and reappearance occurs strongly indicate that renal
vasoconstriction is the primary effect of CsA acute dysfunction,
and that dopamine counteracts this effect in humans. Recently,
it has been demonstrated in experimental animals that both
renal vasodilators, as misoprostol [371, and antivasoconstrictive
agents, as phenoxibenzamine [2], and renal denervation [38]
can completely reverse the effects of CsA on renal plasma flow.
These findings indicate that the beneficial vascular effects of
dopamine are not specific to this agent and its receptors.
In normal subjects, dopamine infusion is known to increase
sodium chloride excretion by reducing proximal tubular reab-
sorption [24]. Such an effect may have contributed (in addition
to the normalized glomerular dynamics) to the increase of
fractional excretion of sodium observed in our study with CsA
plus dopamine. The augmented delivery of sodium chloride
during dopamine infusion restored the fractional generation of
free-water (CH2O/CIfl) to normal, previously reduced by CsA
alone. The increased osmolar load, however, did not allow the
achievement of the minimal urinary osmolality obtained during
control period.
Also, Kho et al [39] have studied the influence of dopamine
infusion on renal hemodynamics in CsA-treated renal transplant
patients. In this paper, however, the patients were examined
after chronic treatment with CsA and had impairment of renal
function. In such conditions, the infusion of dopamine slightly
increased the "effective" renal plasma flow without changing
GFR. But, the measurement of "effective" renal plasma flow,
performed by Kho et a! [391, by using a radioisotope infusion
method without venous catheterization is not adequate in
conditions of renal failure; no information is given concerning
radioisotope infusion method, renal clearances periods, statis-
tical methods, cause of renal failure, etc.
Taken together, the findings of the protocols A and B in
relation to tubular function indicate that the tubular alterations
induced by CsA may be explained by renal hemodynamic
changes rather than by direct effects of the drug on tubular
epithelial cells, and than these dysfunctions can be overcome
by dopamine infusion, suggesting a vascular disturbance. These
statements must be restricted to the very short period of the
investigation. Indeed, our study does not conclusively rule out
the possibility that direct tubular insults are occurring or will
occur in time and/or that the vascular effects might not take
place after repeated doses of CsA over many days.
PRA, aldosterone plasma levels and urinary excretion of
epinephrine and norepinephrine were not affected by CsA, nor
by dopamine in our studies. Thus, neither the renin-angiotensin
system nor the sympathetic nervous system appear to be
involved in the changes of renal hemodynamics secondary to
CsA and/or dopamine administration in humans. Undoubtedly,
other hormonal factors, such as prostaglandins and trombox-
ane, may play some role in CsA-induced nephrotoxicity but
their involvement in humans has still to be defined.
In conclusion, our data indicate that: (i) a single oral dose of
CsA (12 mg/kg body wt) causes marked renal hypoperfusion,
impairment in GFR, increase in FF and proximal tubular
overreabsorption with fall of fractional urine and sodium excre-
tion and, consequently, reduction in the renal ability to generate
1092 Conte et a!: GSA and dopamine in healthy patients
free-water (CH2O); (ii) the acute changes of glomerular and
tubular function, observed after oral CsA, are accounted for by
primary reversible alterations in renal hemodynamics; (iii) these
effects are completely reversed by dopamine infusion at low
dosage.
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